As the popularity of GLP-1 receptor agonists (GLP1ra)—such as semaglutide and liraglutide—reaches unprecedented heights, the ripple effects are being felt far beyond the endocrinology clinic. In the operating rooms of plastic surgeons across the United States, a new clinical reality is taking shape. Patients who have achieved significant weight loss through these medications are increasingly seeking body contouring procedures to address the resulting loose, hanging skin.
However, a groundbreaking study published in the April issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS), suggests that while these medications are transforming weight management, they may be introducing a complex, "nuanced" set of variables into the recovery process following abdominal panniculectomy.
The New Frontier: GLP-1s and the Plastic Surgery Suite
Body contouring procedures, specifically the panniculectomy—a surgery to remove the "apron" of excess skin and fat from the lower abdomen—are becoming standard for patients who have successfully navigated massive weight loss. These procedures are not merely cosmetic; they are often functional, alleviating chronic skin irritation, hygiene issues, and mobility challenges.
As the prescription rate for GLP-1 medications has surged, plastic surgeons have found themselves at a crossroads. Some surgeons are actively prescribing these agents to help patients reach an optimal body mass index (BMI) before surgery, hoping to minimize risks associated with obesity. Others are treating patients who have already been on these regimens for months or years. Until now, the clinical impact of these medications on surgical wound healing remained largely anecdotal and under-researched.
A Ten-Year Retrospective: Examining the Data
To better understand this evolving landscape, a team of researchers led by Dr. Zachary Andrew Koenig of the West Virginia University School of Medicine conducted an extensive retrospective analysis. The study scrutinized the outcomes of 373 patients who underwent non-bariatric panniculectomy at their medical center between 2013 and 2023.
The methodology was designed to isolate the impact of GLP-1 use from other variables. The study strictly excluded patients undergoing simultaneous bariatric or hernia surgery, ensuring that the complications recorded could be attributed to the abdominal skin removal itself, rather than complex internal surgery.
The Demographic Breakdown
The findings revealed a striking trend: 21.7% of the cohort was actively using GLP-1 medications prior to their surgery. Perhaps most notably, the researchers observed that this percentage saw a sharp, upward trajectory in the most recent years of the study, mirroring the broader national trend of increased GLP-1 utilization.
When comparing the GLP-1 group to those who were not on the medication, the researchers identified clear differences in baseline health. Patients using GLP-1s were more likely to present with chronic comorbidities, including:
- Type 2 diabetes
- Hypertension
- Chronic Obstructive Pulmonary Disease (COPD)
Interestingly, despite the difference in medical history, there was no statistically significant difference in the BMI between the two groups, suggesting that the GLP-1 cohort was not necessarily "healthier" or "thinner" at the time of surgery, but rather managing more complex systemic conditions.
Complications: The "Complex and Nuanced" Interplay
The primary concern for any surgeon performing a panniculectomy is the integrity of the wound. The study’s results painted a paradoxical picture of how GLP-1 medications interact with the body’s healing mechanisms.
Delayed Wound Healing
The most concerning finding for surgeons was the rate of delayed wound healing. Among the GLP-1 users, 18.5% experienced delays in the healing process, a figure significantly higher than the 7.5% observed in the non-GLP-1 group. This suggests that the physiological changes induced by GLP-1 receptor agonists—which can affect metabolic rate and potentially alter inflammatory responses—may interfere with the body’s ability to knit tissue together efficiently after an invasive procedure.
The Seroma Paradox
Conversely, the study yielded a surprising protective finding: a lower rate of seroma (fluid accumulation under the skin) in the GLP-1 group. Patients on the medication experienced seroma at a rate of 4.9%, compared to 14.0% in the control group.
While the exact mechanism remains a subject of hypothesis, the researchers suggest that the unique metabolic environment created by these drugs might influence lymphatic drainage or fluid retention in the abdominal area. This inverse relationship—increased risk of healing delay alongside decreased risk of fluid buildup—highlights the "complex and nuanced" nature of the drug’s impact on soft tissue.
Clinical Implications: A Call for Proactive Management
The findings from Dr. Koenig and his team do not suggest that surgeons should categorically reject patients on GLP-1s. Instead, the study serves as a call for a more sophisticated, individualized approach to perioperative care.
The Need for Standardized Protocols
Currently, there are no uniform, society-wide guidelines on whether patients should pause GLP-1 treatment before elective plastic surgery. Some surgeons advocate for a "washout" period—where the patient stops the medication for several weeks before the operation—to potentially mitigate risks. Others argue that the stability provided by the medication outweighs the potential risks of withdrawal or weight rebound.
The West Virginia study emphasizes that while GLP-1s appear broadly safe in a perioperative setting—as evidenced by the lack of increase in major complications like severe infections or high rehospitalization rates—the specific, subtle issues like delayed healing demand a new level of vigilance.
Surgeon and Patient Communication
For the patient, this means the pre-operative consultation must now include a deep dive into medication history. Surgeons are encouraged to:
- Map the Timeline: Document exactly when the patient began the GLP-1, the dosage, and the expected duration of the treatment.
- Screen for Comorbidities: Because GLP-1 patients often have underlying metabolic conditions, surgeons should ensure that blood glucose levels and other metabolic markers are optimized before anesthesia is administered.
- Adjust Post-Operative Expectations: If a patient is identified as a high-risk candidate for delayed healing, surgeons may consider longer intervals between post-operative follow-ups, additional wound care support, or the use of specific compression garments to manage fluid and support tissue tension.
The Future of Research
As West Virginia has one of the highest rates of GLP-1 prescriptions in the nation, this study serves as a "canary in the coal mine" for the rest of the medical community. The data provides a valuable baseline, but it also highlights the urgent need for larger, multi-center, and potentially prospective studies.
"Our findings suggest that while GLP1ra therapy does not appear to increase major surgical risk, it may affect specific aspects of healing that warrant proactive management," Dr. Koenig and his coauthors noted.
The medical community is now tasked with answering the next set of questions:
- Does the duration of GLP-1 use matter more than the dosage?
- Do different brands of GLP-1 agonists (e.g., semaglutide vs. tirzepatide) have different effects on skin and fat tissue?
- Would a structured "cessation protocol" significantly reduce the 18.5% rate of delayed wound healing without compromising the patient’s weight loss trajectory?
Conclusion
The integration of GLP-1 receptor agonists into the mainstream of patient care is one of the most significant medical developments of the decade. For the field of plastic surgery, it offers a pathway to treat patients who were previously considered poor candidates for body contouring due to obesity.
However, the findings in Plastic and Reconstructive Surgery® serve as a crucial reminder that surgical success is rarely about a single factor. It is the result of thousands of microscopic cellular processes—processes that medications like GLP-1s can fundamentally alter. As the field moves forward, the collaboration between endocrinologists, primary care providers, and plastic surgeons will be essential.
By shifting from a "one-size-fits-all" model to a more tailored, evidence-based approach, plastic surgeons can continue to provide life-changing outcomes for patients in the post-weight-loss era, ensuring that the final stage of their journey—the removal of the skin that once held their former weight—is as safe and successful as the weight loss that preceded it.
About the Source
Plastic and Reconstructive Surgery® is the official journal of the American Society of Plastic Surgeons. Published by Wolters Kluwer, the journal is a leading source of research and clinical innovation in the field, providing surgeons with the data needed to advance patient care and safety. This specific study, titled "Perioperative GLP-1 Receptor Agonist Use and Surgical Outcomes in Nonbariatric Abdominal Panniculectomy: A 10-Year Retrospective Analysis," is a critical contribution to the evolving understanding of pharmacological impacts on surgical outcomes.
About the Author
